WO2004056389A1 - Hpv-16 and -18 l1 vlp vaccine - Google Patents
Hpv-16 and -18 l1 vlp vaccine Download PDFInfo
- Publication number
- WO2004056389A1 WO2004056389A1 PCT/EP2003/014562 EP0314562W WO2004056389A1 WO 2004056389 A1 WO2004056389 A1 WO 2004056389A1 EP 0314562 W EP0314562 W EP 0314562W WO 2004056389 A1 WO2004056389 A1 WO 2004056389A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hpv
- types
- group
- infection
- vlp
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 52
- 208000015181 infectious disease Diseases 0.000 claims abstract description 61
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims description 49
- 230000002265 prevention Effects 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 31
- 231100000590 oncogenic Toxicity 0.000 claims description 23
- 230000002246 oncogenic effect Effects 0.000 claims description 23
- 239000002671 adjuvant Substances 0.000 claims description 22
- 229940068196 placebo Drugs 0.000 claims description 20
- 239000000902 placebo Substances 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 14
- 230000028993 immune response Effects 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 7
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 6
- 159000000013 aluminium salts Chemical class 0.000 claims description 5
- 229910000329 aluminium sulfate Inorganic materials 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 4
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 3
- 230000001681 protective effect Effects 0.000 claims description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 description 175
- 206010028980 Neoplasm Diseases 0.000 description 31
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 25
- 201000011510 cancer Diseases 0.000 description 25
- 150000007949 saponins Chemical class 0.000 description 17
- 229930182490 saponin Natural products 0.000 description 16
- 235000017709 saponins Nutrition 0.000 description 16
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 13
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 208000009608 Papillomavirus Infections Diseases 0.000 description 9
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 239000004411 aluminium Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000701828 Human papillomavirus type 11 Species 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 241000219287 Saponaria Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 238000009595 pap smear Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241001316290 Gypsophila Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000709701 Human poliovirus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000607149 Salmonella sp. Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001399 aluminium compounds Chemical class 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 239000002812 cholic acid derivative Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Description
Claims
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT03789346T ATE503492T1 (en) | 2002-12-20 | 2003-12-18 | USE OF HPV16 AND HPV18 VLPS AS VACCINES AGAINST ONE OR MORE ONCOGENIC HPV TYPE 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
SI200332003T SI1572233T1 (en) | 2002-12-20 | 2003-12-18 | Use of HPV16 and HPV18 as vaccine against one or more of oncogenic HPV type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
JP2005502554A JP5475939B2 (en) | 2002-12-20 | 2003-12-18 | HPV-16 and HPV-18L1 VLP vaccine |
MXPA05006764A MXPA05006764A (en) | 2002-12-20 | 2003-12-18 | Hpv-16 and -18 l1 vlp vaccine. |
DE60336581T DE60336581D1 (en) | 2002-12-20 | 2003-12-18 | Use of HPV16 and HPV18 VLPs as vaccines against one or more oncogenic HPV of types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
US10/540,099 US20060251676A1 (en) | 2002-12-20 | 2003-12-18 | Hpv-16 and-18 l1 vlp vaccine |
AP2005003347A AP2005003347A0 (en) | 2002-12-20 | 2003-12-18 | HPV-16 and-18 Lu VLP vaccine |
EP03789346A EP1572233B1 (en) | 2002-12-20 | 2003-12-18 | Use of HPV16 and HPV18 as vaccine against one or more of oncogenic HPV type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
EA200500834A EA009179B1 (en) | 2002-12-20 | 2003-12-18 | Hpv-16 and -18 l1 vlp vaccine |
AU2003293942A AU2003293942B2 (en) | 2002-12-20 | 2003-12-18 | HPV-16 and -18 L1 VLP vaccine |
CA2510457A CA2510457C (en) | 2002-12-20 | 2003-12-18 | Hpv-16 and -18 l1 vlp vaccine |
BR0317544-8A BR0317544A (en) | 2002-12-20 | 2003-12-18 | Use of a composition comprising hpv 16 and hpv 18 vlps, and methods for eliciting an immune response against one or more of the oncogenic hpv type group, to prevent infection and / or disease caused by one or more of the type group oncogenic hpv, to prevent infection of a patient population by one or more hpv types, use of a mixture of hpv 16 and hpv18 vlps, and vaccine composition |
DK03789346.8T DK1572233T3 (en) | 2002-12-20 | 2003-12-18 | Use of HPV16 and HPV18 as a vaccine against one or more oncogenic HPV viruses of types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
NZ540811A NZ540811A (en) | 2002-12-20 | 2003-12-18 | Use of HPV 16 and HPV 18 VLPs in the prevention of infection or disease caused by one or more of the group of oncogenic HPV types excluding types 16 and 18 |
KR1020127027784A KR101361769B1 (en) | 2002-12-20 | 2003-12-18 | Hpv-16 and -18 l1 vlp vaccine |
US11/114,301 US20050287161A1 (en) | 2002-12-20 | 2005-04-26 | Vaccine |
IS7885A IS2811B (en) | 2002-12-20 | 2005-06-09 | Use of HPV16 and HPV18 virus-like particles against one or more of the tumor-causing HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
IL169085A IL169085A (en) | 2002-12-20 | 2005-06-09 | Vaccine composition comprising human papilloma (hpv) hpv-16 and hpv-18 virus like particles and its use in the preparation of a medicament for preventing disease caused by oncogenic hpv type |
NO20052846A NO20052846L (en) | 2002-12-20 | 2005-06-13 | HPV-16 and -18 L1 VLP vaccine. |
US11/367,601 US7858098B2 (en) | 2002-12-20 | 2005-12-16 | Vaccine |
HK06102781.3A HK1085378A1 (en) | 2002-12-20 | 2006-03-02 | Use of hpv16 and hpv18 as vaccine against one or more of oncogenic hpv type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43503502P | 2002-12-20 | 2002-12-20 | |
US60/435,035 | 2002-12-20 | ||
US49665303P | 2003-08-20 | 2003-08-20 | |
US60/496,653 | 2003-08-20 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/114,301 Continuation-In-Part US20050287161A1 (en) | 2002-12-20 | 2005-04-26 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004056389A1 true WO2004056389A1 (en) | 2004-07-08 |
Family
ID=32685362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/014562 WO2004056389A1 (en) | 2002-12-20 | 2003-12-18 | Hpv-16 and -18 l1 vlp vaccine |
Country Status (28)
Country | Link |
---|---|
US (2) | US20060251676A1 (en) |
EP (1) | EP1572233B1 (en) |
JP (1) | JP5475939B2 (en) |
KR (3) | KR20050086924A (en) |
AP (1) | AP2005003347A0 (en) |
AR (1) | AR042530A1 (en) |
AT (1) | ATE503492T1 (en) |
AU (1) | AU2003293942B2 (en) |
BR (1) | BR0317544A (en) |
CA (1) | CA2510457C (en) |
CY (1) | CY1111552T1 (en) |
DE (1) | DE60336581D1 (en) |
DK (1) | DK1572233T3 (en) |
EA (2) | EA009179B1 (en) |
EC (1) | ECSP055869A (en) |
HK (1) | HK1085378A1 (en) |
IL (1) | IL169085A (en) |
IS (1) | IS2811B (en) |
MA (1) | MA27581A1 (en) |
MX (1) | MXPA05006764A (en) |
MY (1) | MY144492A (en) |
NO (1) | NO20052846L (en) |
NZ (1) | NZ540811A (en) |
OA (1) | OA13147A (en) |
PL (1) | PL215257B1 (en) |
PT (1) | PT1572233E (en) |
TW (1) | TWI349557B (en) |
WO (1) | WO2004056389A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005123125A1 (en) * | 2004-06-16 | 2005-12-29 | Glaxosmithkline Biologicals S.A. | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
WO2006113209A1 (en) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
WO2006114312A2 (en) * | 2005-04-26 | 2006-11-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
WO2006114273A2 (en) * | 2005-04-26 | 2006-11-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
US7357936B1 (en) | 1998-10-16 | 2008-04-15 | Smithkline Beecham Biologicals, Sa | Adjuvant systems and vaccines |
EP2154147A1 (en) * | 2007-04-29 | 2010-02-17 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | A truncated l1 protein of human papillomavirus 16 |
US7758866B2 (en) | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
WO2010099580A1 (en) * | 2009-03-05 | 2010-09-10 | Jenny Colleen Mccloskey | Treatment of infection |
US7815915B2 (en) | 2002-03-18 | 2010-10-19 | Glaxosmithkline Biologicals, S.A. | Mixture of human papillomavirus virus-like particles |
US7858098B2 (en) | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
WO2015114506A2 (en) | 2014-01-31 | 2015-08-06 | Marini Bruna | Biosensor for the determination of infections and associated pathologies |
US9364529B2 (en) | 2007-04-29 | 2016-06-14 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of human papillomavirus type 18 |
EP3305320A4 (en) * | 2015-06-02 | 2019-01-23 | Terumo Kabushiki Kaisha | Aluminum-containing adjuvant composition, and vaccine composition containing same |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009348078B2 (en) * | 2009-06-19 | 2013-03-14 | Eyegene Inc. | Vaccine for cervical cancer |
AU2015335652B2 (en) | 2014-10-24 | 2020-07-02 | Hpvvax, Llc. | Cancer and skin lesion treatment |
US10799574B2 (en) | 2014-10-24 | 2020-10-13 | Hpvvax. Llc | Method and composition for treating cancer or skin lesion using a vaccine |
CA3092935A1 (en) | 2018-03-06 | 2019-09-12 | Precigen, Inc. | Hepatitis b vaccines and uses of the same |
US20210024586A1 (en) * | 2018-03-06 | 2021-01-28 | Precigen, Inc. | Human papillomavirus vaccines and uses of the same |
EP3812395A4 (en) * | 2018-06-04 | 2022-03-30 | Xiamen University | Mutant of human papillomavirus 18 l1 protein |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4332596A1 (en) * | 1993-09-24 | 1995-03-30 | Martin Josef Dr Sapp | Monoclonal antibodies |
WO1999013056A1 (en) | 1997-09-05 | 1999-03-18 | Medimmune, Inc. | IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs) |
WO2001017551A2 (en) * | 1999-09-07 | 2001-03-15 | Smithkline Beecham Biologicals S.A. | Combined vaccine compositions |
US6245568B1 (en) | 1999-03-26 | 2001-06-12 | Merck & Co., Inc. | Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
US6251678B1 (en) * | 1999-02-05 | 2001-06-26 | Merck & Co., Inc. | Human papillomavirus vaccine formulations |
WO2001097840A1 (en) * | 2000-06-21 | 2001-12-27 | Medimmune, Inc. | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ523408A (en) * | 2000-06-26 | 2006-02-24 | Stressgen Biotechnologies Corp | Human papilloma virus treatment |
-
2003
- 2003-12-18 KR KR1020057011497A patent/KR20050086924A/en active Application Filing
- 2003-12-18 BR BR0317544-8A patent/BR0317544A/en not_active Application Discontinuation
- 2003-12-18 KR KR1020127027784A patent/KR101361769B1/en active IP Right Grant
- 2003-12-18 AT AT03789346T patent/ATE503492T1/en active
- 2003-12-18 DK DK03789346.8T patent/DK1572233T3/en active
- 2003-12-18 MX MXPA05006764A patent/MXPA05006764A/en active IP Right Grant
- 2003-12-18 JP JP2005502554A patent/JP5475939B2/en not_active Expired - Lifetime
- 2003-12-18 DE DE60336581T patent/DE60336581D1/en not_active Expired - Lifetime
- 2003-12-18 NZ NZ540811A patent/NZ540811A/en not_active IP Right Cessation
- 2003-12-18 PL PL377710A patent/PL215257B1/en unknown
- 2003-12-18 MY MYPI20034868A patent/MY144492A/en unknown
- 2003-12-18 OA OA1200500189A patent/OA13147A/en unknown
- 2003-12-18 CA CA2510457A patent/CA2510457C/en not_active Expired - Lifetime
- 2003-12-18 AU AU2003293942A patent/AU2003293942B2/en not_active Expired
- 2003-12-18 EA EA200500834A patent/EA009179B1/en not_active IP Right Cessation
- 2003-12-18 KR KR1020127026719A patent/KR20120118087A/en not_active Application Discontinuation
- 2003-12-18 EP EP03789346A patent/EP1572233B1/en not_active Expired - Lifetime
- 2003-12-18 PT PT03789346T patent/PT1572233E/en unknown
- 2003-12-18 EA EA200701633A patent/EA200701633A1/en unknown
- 2003-12-18 WO PCT/EP2003/014562 patent/WO2004056389A1/en active Application Filing
- 2003-12-18 TW TW092135963A patent/TWI349557B/en not_active IP Right Cessation
- 2003-12-18 AR ARP030104709A patent/AR042530A1/en unknown
- 2003-12-18 AP AP2005003347A patent/AP2005003347A0/en unknown
- 2003-12-18 US US10/540,099 patent/US20060251676A1/en not_active Abandoned
-
2005
- 2005-04-26 US US11/114,301 patent/US20050287161A1/en not_active Abandoned
- 2005-06-09 IS IS7885A patent/IS2811B/en unknown
- 2005-06-09 IL IL169085A patent/IL169085A/en active IP Right Grant
- 2005-06-13 NO NO20052846A patent/NO20052846L/en not_active Application Discontinuation
- 2005-06-20 EC EC2005005869A patent/ECSP055869A/en unknown
- 2005-07-18 MA MA28398A patent/MA27581A1/en unknown
-
2006
- 2006-03-02 HK HK06102781.3A patent/HK1085378A1/en not_active IP Right Cessation
-
2011
- 2011-06-08 CY CY20111100549T patent/CY1111552T1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4332596A1 (en) * | 1993-09-24 | 1995-03-30 | Martin Josef Dr Sapp | Monoclonal antibodies |
WO1999013056A1 (en) | 1997-09-05 | 1999-03-18 | Medimmune, Inc. | IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs) |
US6251678B1 (en) * | 1999-02-05 | 2001-06-26 | Merck & Co., Inc. | Human papillomavirus vaccine formulations |
US6245568B1 (en) | 1999-03-26 | 2001-06-12 | Merck & Co., Inc. | Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
WO2001017551A2 (en) * | 1999-09-07 | 2001-03-15 | Smithkline Beecham Biologicals S.A. | Combined vaccine compositions |
WO2001097840A1 (en) * | 2000-06-21 | 2001-12-27 | Medimmune, Inc. | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
Non-Patent Citations (11)
Title |
---|
BACHTIARY BARBARA ET AL: "Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. UNITED STATES 20 NOV 2002, vol. 102, no. 3, 20 November 2002 (2002-11-20), pages 237 - 243, XP002278801, ISSN: 0020-7136 * |
BALSLEY JF ET AL: "Progress in the development of human papillomavirus vaccines for HPV-11 and HPV-16/18 and mapping of a critical neutralizing epitope.", 18TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE 2000, 2000, XP002278802, Retrieved from the Internet <URL:http://www.hpv2000.com/idabstract.asp?id=366> [retrieved on 20040503] * |
BASS E: "Progress in the Search of a vaccine against human papilloma virus", IAVI REPORT OCTOBER/NOVEMBER 2002, 10 October 2002 (2002-10-10), XP002281262, Retrieved from the Internet <URL:www.aegis.com/pubs/iavi/2002/IAVI2002-1003.html> [retrieved on 20040421] * |
BREITBURD, SEMINARS IN CANCER BIOLOGY, vol. 9, 1999, pages 431 - 445 |
COMBITA ALBA-LUCIA ET AL: "Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.", JOURNAL OF VIROLOGY. UNITED STATES JUL 2002, vol. 76, no. 13, July 2002 (2002-07-01), pages 6480 - 6486, XP002278799, ISSN: 0022-538X * |
MCCARTHY ET AL.: "Quantitative Disassembly and Reassembly of Human Papillomavirus Type 11 Viruslike Particles in Vitro", J. VIROLOGY, vol. 72, no. 1, 1998, pages 33 - 41 |
SCHILLER J T ET AL: "PAPILLOMAVIRUS-LIKE PARTICLE BASED VACCINES: CERVICAL CANCER AND BEYOND", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 1, no. 4, July 2001 (2001-07-01), pages 571 - 581, XP008028179, ISSN: 1471-2598 * |
STELLER MICHAEL A: "Cervical cancer vaccines: progress and prospects.", JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION. UNITED STATES 2002 SEP-OCT, vol. 9, no. 5, September 2002 (2002-09-01), pages 254 - 264, XP002278800, ISSN: 1071-5576 * |
SUZICH, J. A. ET AL., PROC NATL ACAD SCI, vol. 92, 1995, pages 11553 - 11557 |
VILLA L, ET AL: "A DOSE-RANGING SAFETY AND IMMUNOGENICITY STUDY OF A QUADRIVALENT HPV/TYPES 6/11/16/18) L1 VLP VACCINE IN WOMEN", HPV. INTERNATIONAL PAPILLOMAVIRUS CONFERENCE, XX, XX, 4 October 2002 (2002-10-04) - 9 October 2002 (2002-10-09), XX, pages 1, XP002281268 * |
XX; 1 September 2001 (2001-09-01), BROWN D R, ET AL: "A DOSE-RANGING STUDY OF THE SAFETY AND IMMUNOGENICITY PROFILES OF A QUADRIVALENT HPV (TYPES 6,11,16, AND 18) L1 VLP CANDIDATE VACCINE IN YOUNG HEALTHY WOMEN", XP002278803, Database accession no. O-51 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8628784B2 (en) | 1998-10-16 | 2014-01-14 | Glaxosmithkline Biologicals S.A. | Adjuvant systems and vaccines |
US7357936B1 (en) | 1998-10-16 | 2008-04-15 | Smithkline Beecham Biologicals, Sa | Adjuvant systems and vaccines |
US7815915B2 (en) | 2002-03-18 | 2010-10-19 | Glaxosmithkline Biologicals, S.A. | Mixture of human papillomavirus virus-like particles |
US7858098B2 (en) | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
US7758866B2 (en) | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
WO2005123125A1 (en) * | 2004-06-16 | 2005-12-29 | Glaxosmithkline Biologicals S.A. | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
WO2006113209A1 (en) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
US7691579B2 (en) | 2005-04-15 | 2010-04-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
JP2008539184A (en) * | 2005-04-26 | 2008-11-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | vaccine |
JP2008539182A (en) * | 2005-04-26 | 2008-11-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | vaccine |
WO2006114312A3 (en) * | 2005-04-26 | 2007-04-05 | Glaxosmithkline Biolog Sa | Vaccine |
EA013326B1 (en) * | 2005-04-26 | 2010-04-30 | Глаксосмитклайн Байолоджикалс С.А. | Vaccine |
EA013325B1 (en) * | 2005-04-26 | 2010-04-30 | Глаксосмитклайн Байолоджикалс С.А. | Vaccine |
WO2006114273A3 (en) * | 2005-04-26 | 2007-03-15 | Glaxosmithkline Biolog Sa | Vaccine |
WO2006114273A2 (en) * | 2005-04-26 | 2006-11-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
WO2006114312A2 (en) * | 2005-04-26 | 2006-11-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
US9364529B2 (en) | 2007-04-29 | 2016-06-14 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of human papillomavirus type 18 |
US9428555B2 (en) | 2007-04-29 | 2016-08-30 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of Human Papillomavirus type 16 |
EP2154147A1 (en) * | 2007-04-29 | 2010-02-17 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | A truncated l1 protein of human papillomavirus 16 |
EP2154147B1 (en) * | 2007-04-29 | 2015-10-07 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | A truncated l1 protein of human papillomavirus 16 |
US20140186406A1 (en) * | 2009-03-05 | 2014-07-03 | Jenny Colleen McCloskey | Treatment of Infection |
US20160166682A1 (en) * | 2009-03-05 | 2016-06-16 | Jenny Colleen McCloskey | Treatment of Infection |
WO2010099580A1 (en) * | 2009-03-05 | 2010-09-10 | Jenny Colleen Mccloskey | Treatment of infection |
US20170173148A1 (en) * | 2009-03-05 | 2017-06-22 | Jenny Colleen McCloskey | Treatment of Infection |
US10086069B2 (en) * | 2009-03-05 | 2018-10-02 | Jenny Colleen McCloskey | Treatment of infection |
US20180353601A1 (en) * | 2009-03-05 | 2018-12-13 | Jenny Colleen McCloskey | Treatment of Infection |
US10617754B2 (en) | 2009-03-05 | 2020-04-14 | Jenny Colleen McCloskey | Treatment of infection |
AU2018267595B2 (en) * | 2009-03-05 | 2020-09-03 | Jenny Colleen Mccloskey | Treatment of infection |
US11033618B2 (en) | 2009-03-05 | 2021-06-15 | Jenny Colleen McCloskey | Treatment of infection |
WO2015114506A2 (en) | 2014-01-31 | 2015-08-06 | Marini Bruna | Biosensor for the determination of infections and associated pathologies |
EP3305320A4 (en) * | 2015-06-02 | 2019-01-23 | Terumo Kabushiki Kaisha | Aluminum-containing adjuvant composition, and vaccine composition containing same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL169085A (en) | Vaccine composition comprising human papilloma (hpv) hpv-16 and hpv-18 virus like particles and its use in the preparation of a medicament for preventing disease caused by oncogenic hpv type | |
JP2004531540A (en) | HIV antigens and multivalent vaccines containing HSV and / or HPV antigens | |
CA2566620C (en) | Vaccine against hpv16 and hpv18 and at least another hpv type slected from hpv 31, 45 or 52 | |
JP2012102132A (en) | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 | |
KR20080005585A (en) | Vaccine | |
WO2004052395A1 (en) | L2-peptide of the human papillomavirus associated with virus-like particles | |
ZA200504907B (en) | HPV-16 and -18 L1 VLP vaccine | |
US7858098B2 (en) | Vaccine | |
US20080014220A1 (en) | Vaccine Against Hpv16 And Hpv18 And At Least Another Hpv Type Selected From Hpv 31, 45 Or 52 | |
ES2361913T3 (en) | USE OF HPV16 AND HPV18 AS VACCINES WITH ONE OR MORE ONCOGENS OF TYPES 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68. | |
WO2006114273A2 (en) | Vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11114301 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 169085 Country of ref document: IL Ref document number: 1108/KOLNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/04907 Country of ref document: ZA Ref document number: 05058242 Country of ref document: CO Ref document number: 200504907 Country of ref document: ZA Ref document number: 200500834 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2510457 Country of ref document: CA Ref document number: 2005502554 Country of ref document: JP Ref document number: 2003293942 Country of ref document: AU Ref document number: 540811 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-501161 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057011497 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/006764 Country of ref document: MX Ref document number: AP/P/2005/003347 Country of ref document: AP Ref document number: 377710 Country of ref document: PL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003789346 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2005000239 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200501023 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A97292 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057011497 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003789346 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0317544 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006251676 Country of ref document: US Ref document number: 10540099 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10540099 Country of ref document: US |